Original Article The association between the FABP2 Ala54Thr variant and the risk of type 2 diabetes mellitus: a meta-analysis based on 11 case-control studies

Peng Liu, Dan Yu, Xiaoping Jin, Cai Li, Feng Zhu, Zhou Zheng, Chenlin Lv, Xinwei He

Department of Neurology, Taizhou Hospital, Affiliated Hospital of Wenzhou Medical University, China

Received December 29, 2014; Accepted March 17, 2015; Epub April 15, 2015; Published April 30, 2015

Abstract: Fatty acid binding protein 2 (FABP2) Ala54Thr gene polymorphism has been suggested to be associated with the increased risk of developing type 2 diabetes mellitus (T2DM), but some studies show the inconsistent result. The purpose of this meta-analysis is to assess the association between FABP2 Ala54Thr gene polymorphism variants and the T2DM. A total of 7095 subjects in 11 case-control studies were included in this meta-analysis. Under the allele model (T versus A), the pooled OR of Asian subgroup was 1.19 (95% CI = 1.06-1.32, P = 0.002). Under the recessive model (TT versus AA + AT), the pooled OR of Asian subgroup was 1.34 (95% CI = 1.05-1.71, P = 0.02). Under the dominant model (TT + AT versus AA), the pooled OR was 1.14 (95% CI = 1.03-1.27, P = 0.01) and when the analysis stratified by region, increased risks were identified among Asian (OR = 1.20, 95% CI = 1.05-1.38, P = 0.009). Under the codominant model (TT versus AA), no significant association was found. Under the codominant model (AT versus AA), the pooled OR was 1.14 (95% CI = 1.02-1.27, P = 0.02). It is indicated that the variant T allele carrier may increased the risk of T2DM and the risk is related to race.

Keywords: Diabetes mellitus, fatty acid-binding protein 2, polymorphism, meta-analysis

Introduction

Type 2 diabetes mellitus (T2DM) is a chronic, complex metabolic disorder. It is widely known that environmental factors contribute to the development of T2DM, but the specific role of genetic can not be ruled out, the genetical susceptibility being expressed under the influence of environmental factors [1]. Over the past few years, epidemiological studies have identified multiple genetic susceptibility variants for T2DM. Current genome-wide association studies and genome-wide linkage analysis identified several variants corresponding to risk prediction of T2DM, including Transcription factor 7-like 2 (TCF7L2) [2], Fat Mass and Obesity associated gene (FTO) [3], Peroxisome Proliferator-Activated Receptor Gamma (PPAR-y) [4], Interleukin-10 (IL-10) [5] and Ectoenzyme Nucleotide Pyrophosphate Phosphodiesterase 1 (ENPP1) [6]. Recently, an underlying candidate gene fatty acid binding protein 2 (FABP2) was shown to play a part in T2DM occurrence.

Fatty acid-binding proteins were first found by Ockner in 1970s. The fatty acid binding protein

2 (FABP2) gene that located on 4q28-q31 chromosomal region and codes for the intestinal FABP is a member of the FABPs superfamily [7]. The G to A mutation at codon 54 of FABP2 results in the substitution of threonine (Thr) for alanine (Ala) [8]. Over the past decades, a number of case-control studies were conducted to investigate the association between this change and T2DM risk. As a result, more and more FABP2 Ala54Thr polymorphism studies have been detected in different cohorts of T2DM patients with different ethnical or geographical origins. Nevertheless, the conclusions of these studies still remain equivocal.

In 2014, Alharbi et al indicated that FABP2 gene is not potential contributor to the risk of T2DM in a Saudi population [9]. In 2013, Raza et al reported that significant differences were not observed in the genotypic and allele frequencies between the T2DM cases and controls in a Northern India population [10]. In 2009, Tavridou et al found that no significant difference was found in genotypes between diabetic and nondiabetic subjects in a Greek Caucasian

Author	Veer	Country	Region	Study	Construction	T2DM			Control				Sample size
Author	rear			design	Genotyping	TT	AT	AA	TT	AT	AA	P _{HWE}	(T2DM/Control)
Alharbi [9]	2014	Saudi	Asia	Case-control	TaqMan	37	170	220	29	171	260	0.90	887 (427/460)
Bu [19]	2011	USA	North America	Case-control	PCR-RFLP	163	107	23	187	94	17	0.26	591 (293/298)
Tavridou [11]	2009	Greek	Europe	Case-control	PCR-RFLP	24	104	114	13	71	104	0.85	430 (242/188)
Fisher [14]	2006	Germany	Europe	Case-control	pyrosequencing	14	84	93	37	162	183	0.89	573 (191/382)
Vimaleswaran [12]	2006	India	Asia	Case-control	PCR-RFLP &	73	317	383	64	353	482	0.95	1672 (773/899)
					Direct sequencing								
Tahvanainen [20]	2000	Mix	Europe	Case-control	TaqMan	18	146	166	27	125	184	0.38	666 (330/336)
Hayakawa [21]	1999	Japan	Asia	Case-control	PCR-RFLP	4	5	6	28	86	91	0.29	220 (15/205)
Lei [22]	1999	USA	North	Case-control	PCR-RFLP	12	119	190	48	357	587	0.50	1313 (321/992)
			America										
Ito [23]	1999	Japan	Asia	Case-control	PCR-RFLP	23	76	51	22	62	63	0.30	297 (150/147)
Xiang [24]	1999	China	Asia	Case-control	PCR-RFLP	6	30	25	9	53	54	0.41	177 (61/116)
Yamada [25]	1997	Japan	Asia	Case-control	PCR-RFLP	5	13	14	26	115	96	0.33	269 (32/237)

PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism; Mix: Baltic, United Kingdom, middle and southern Europe. HWE: P value of Hardy-Weinberg equilibrium of controls.



Figure 1. Forest plot of the association between FABP2 Ala54Thr polymorphism and T2DM: the allele model (T versus A).

population [11]. In 2006, Vimaleswaran et al reported that the Ala54Thr polymorphism was not associated with type 2 diabetes mellitus or obesity in a South Indian population [12].

On the contrary, in 2007, Albala et al observed that there was a strong association between the Ala54Thr polymorphism with diabetes in Chilean elders [13]. In 2006, Fisher et al the

T54 allele of FABP2 A54T reduced risk of T2DM in women from a German population [14]. In 1999, Boullu-Sanchis et al found that there was a significant relation between the Ala54Thr FABP2 polymorphism and T2DM [15].

Consensus on whether Ala54Thr FABP2 polymorphism induced an increased risk of T2DM is lacking, by far. To clarify the role of Ala54Thr

				Hetero	geneity		
Genetic contrast	Sample size (T2DM/Control)	OR (95% CI)	Z (P)	P_{h}	 ²	Effect model	
T vs A	5670/8520	1.08 (1.00, 1.17)	2.00 (0.05)	0.21	25%	F	
Asian	2916/4128	1.19 (1.06, 1.32)	3.07 (0.002)*	0.99	0%	F	
Other	2754/4392	0.98 (0.88, 1.10)	0.31 (0.76)	0.13	44%	F	
TT vs AA + AT	2835/4260	1.01 (0.86, 1.20)	0.15 (0.88)	0.14	33%	F	
Asian	1458/2064	1.34 (1.05, 1.71)	2.38 (0.02)*	0.91	0%	F	
Other	1377/2196	0.79 (0.63, 1.00)	2.00 (0.05)	0.47	0%	F	
TT + AT vs AA	2835/4260	1.14 (1.03, 1.27)	2.53 (0.01)*	0.72	0%	F	
Asian	1458/2064	1.20 (1.05, 1.38)	2.60 (0.009)*	0.92	0%	F	
Other	1377/2196	1.07 (0.92, 1.25)	0.92 (0.36)	0.35	10%	F	
TT vs AA	1664/2611	1.09 (0.69, 1.70)	0.36 (0.72)	< 0.1	78%	R	
Asian	498/898	1.12 (0.42, 2.81)	0.18 (0.86)	< 0.1	87%	R	
Other	1166/1713	1.17 (0.92, 1.50)	1.26 (0.21)	0.11	47%	F	
AT vs AA	2456/3770	1.14 (1.02, 1.27)	2.39 (0.02)*	0.87	0	F	
Asian	787/1396	1.14 (0.95, 1.38)	1.42 (0.16)	0.74	0	F	
Other	1669/2374	1.14 (1.00, 1.30)	1.92 (0.05)	0.64	0	F	

Table 2. Summary of meta-analysis of association of FABP2 Ala54Thr polymorphism and T2DM

 P_h : *p*-value for heterogeneity; I²: quantitative estimate for heterogeneity; R: random effect model; F: fixed effect model: *P < 0.05.

variant in T2DM risk, we therefore performed this meta-analysis.

Materials and methods

Publication search and inclusion criteria

PubMed, EMBASE, Web of Science, Cochrane Library, China National Knowledge Infrastructure, Wanfang database and Chinese Biomedical Literature were searched updated to October 2014 for all English and Chinese language publications. The key words were as follows: ("fatty acid binding protein 2" or "fabp2" or "Ala54THr" or "A54T" or "codon 54") and ("type 2 diabetes" or "T2D") and ("polymorphism" or "genotype" or "variant"). Eligible studies required to meet the following criteria: (1) examining the association of FABPs2 Ala54Thr polymorphism with T2DM; (2) be published in a peer-reviewed journal; (3) available data to estimate an odds ratio (OR) with 95% confidence interval (CI); (4) using a useful method for genotyping genetic variations. Studies were excluded if (1) without controls; (2) contained overlapping data; (3) contained incomplete information for data extraction.

Data extraction

The following information was carefully abstracted from eligible publications, including first author, publication year, ethnicity of the study population, the number of genotypes, the genotyping, the number of cases and controls.

Statistical analysis

The allele model (T versus A), recessive model (TT versus AA + AT), dominant model (TT + AT versus AA) and the codominant model (TT versus AA, AT versus AA) were compared using the odds ratio (OR) corresponding to a 95% confidence interval (CI). Subgroup analyses were processed by ethnicity (Asia and other regions). The pooled OR was determined using a Z test with significance set at P < 0.05. A fixed or random effect model was applied in this metaanalysis. The random effect model was performed when the *P* value of heterogeneity test was < 0.10 [16]; otherwise, the fixed effect model was used [17]. The Hardy-Weinberg equilibrium (HWE) was estimated with x² test among the control subjects in each study, at the 5% significant level.

Publication bias was assessed by the funnel plot, and the asymmetry was further assessed by Egger's linear regression test [18].

Results

Studies and populations

Through the search, a total of 21 studies were obtained. Of the 21 studies, 2 were reviews, 3

FABP2 Ala54 Thr variant and risk of T2DM

	T2DM		Control		Odds Ratio			Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% Cl	Year	M-H, Fixed, 95% Cl		
3.1.1 Asian group										
Yamada 1997	5	32	26	237	1.9%	1.50 [0.53, 4.24]	1997			
Hayakawa 1999	4	15	28	205	1.0%	2.30 [0.68, 7.72]	1999			
Ito 1999	23	150	22	147	6.8%	1.03 [0.55, 1.94]	1999			
Xiang 1999	6	61	9	116	2.0%	1.30 [0.44, 3.83]	1999			
Vimaleswaran 2006	73	773	64	899	19.3%	1.36 [0.96, 1.93]	2006			
Alharbi 2014	37	427	29	460	9.2%	1.41 [0.85, 2.34]	2014			
Subtotal (95% CI)		1458		2064	40.2%	1.34 [1.05, 1.71]		•		
Total events	148		178							
Heterogeneity: Chi ² = 1	.52, df =	5 (P = 0	0.91); I ² =	0%						
Test for overall effect: Z	2 = 2.38 (P = 0.0	2)							
3.1.2 Others										
Lei 1999	12	321	48	992	8.1%	0.76 [0.40, 1.46]	1999			
Tahvanainen 2000	18	330	27	336	9.1%	0.66 [0.36, 1.22]	2000			
Fisher 2006	14	191	37	382	8.2%	0.74 [0.39, 1.40]	2006			
Tavridou 2009	24	242	13	188	4.7%	1.48 [0.73, 3.00]	2009			
Bu 2011	163	293	187	298	29.6%	0.74 [0.54, 1.03]	2011			
Subtotal (95% CI)		1377		2196	59.8%	0.79 [0.63, 1.00]		•		
Total events	231		312							
Heterogeneity: Chi ² = 3.58, df = 4 (P = 0.47); l ² = 0%										
Test for overall effect: Z	2 = 2.00 (P = 0.0	5)							
Total (95% CI)		2835		4260	100.0%	1.01 [0.86, 1.20]		•		
Total events	379		490							
Heterogeneity: Chi ² = 14.91, df = 10 (P = 0.14); l ² = 33%										
Test for overall effect: Z	2 = 0.15 (P = 0.8	8)					0.2 0.0 1 2 0 decreased T2DM risk increased T2DM risk		
Test for subgroup differ	ences: C	hi² = 9.	61. df = 1	(P = 0)	.002). I ² =	89.6%		decreased 12DWINSK Increased 12DWINSK		



were not given a complete information which only showed a summation of AT genotype and TT genotype, 1 was repeated published literature, 1 were unpublished in a peer-reviewed journal, 1 was published in Japanese, and 2 were deviating from the HWE. At last, there are 11 articles included in this study which included a total of 2835 T2DM patients and 4260 controls (**Table 1**).

Pooled analyses

Under the allele model (T versus A), no obvious association was detected between Ala54Thr FABP2 polymorphism and T2DM risk (P = 0.05). In the stratified analysis by region, an increased risk of T2DM was identified among Asian group [OR = 1.19, 95% CI (1.06, 1.32), P = 0.002]. However, no association was found in the other regions (**Figure 1**; **Table 2**).

Under the recessive model (TT versus AA + AT), no significant difference was demonstrated (P = 0.88). In the stratified analysis by region, an increased risk of T2DM was identified among Asian group [OR = 1.34, 95% CI (1.05, 1.71), P = 0.02]. But, there is no difference was found in the other regions (**Figure 2**; **Table 2**). Under the dominant model (TT + AT versus AA), a significant association was found [OR = 1.14, 95% CI (1.03, 1.27), P = 0.01]. In the subsection analysis stratified by region, increased risks were identified among Asian [OR = 1.20, 95% CI (1.05, 1.38), P = 0.009] (**Figure 3**; **Table 2**).

Under the codominant model (TT versus AA), no significant association was found between Ala54Thr polymorphism and T2DM risk (P = 0.72). So was subgroup (**Table 2**).

Under the codominant model (AT versus AA), a significant association was found between Ala54Thr FABP2 polymorphism and T2DM risk [OR = 1.14, 95% CI (1.02, 1.27), P = 0.02]. But, no association was found in the stratified analysis by region (**Table 2**).

Bias diagnostics

The funnel plots of the codominant model (AA VS TT) seemed asymmetry (**Figure 4**), and the rest models nearly symmetric by the visual inspection. In order to confirm our judgment, we conduct the Egger's linear regression test. Finally, no significant result was found (P =

FABP2 Ala54 Thr variant and risk of T2DM

	T2DM		Countrol		Odds Ratio			Odds Ratio		
Study or Subgroup	Events	Total	Events	Total	Weight	M-H, Fixed, 95% C	l Year	M-H, Fixed, 95% CI		
4.1.1 Asian group										
Yamada 1997	18	32	141	237	2.2%	0.88 [0.42, 1.84]	1997			
Hayakawa 1999	9	15	114	205	0.9%	1.20 [0.41, 3.49]	1999			
Xiang 1999	36	61	62	116	2.6%	1.25 [0.67, 2.35]	1999			
Ito 1999	99	150	84	147	4.2%	1.46 [0.91, 2.33]	1999			
Vimaleswaran 2006	390	773	417	899	28.0%	1.18 [0.97, 1.43]	2006			
Alharbi 2014	207	427	200	460	14.6%	1.22 [0.94, 1.59]	2014			
Subtotal (95% CI)		1458		2064	52.5%	1.20 [1.05, 1.38]		◆		
Total events	759		1018							
Heterogeneity: Chi ² = 1	.41, df =	5 (P = 0	0.92); I ² =	0%						
Test for overall effect: Z	2 = 2.60 (P = 0.0	09)							
4.1.2 Others										
Lei 1999	131	321	405	992	17.2%	1.00 [0.77, 1.29]	1999			
Tahvanainen 2000	164	330	152	336	11.1%	1.20 [0.88, 1.62]	2000			
Fisher 2006	98	191	199	382	9.5%	0.97 [0.68, 1.37]	2006			
Tavridou 2009	128	242	84	188	6.5%	1.39 [0.95, 2.04]	2009			
Bu 2011	270	293	281	298	3.2%	0.71 [0.37, 1.36]	2011			
Subtotal (95% CI)		1377		2196	47.5%	1.07 [0.92, 1.25]		•		
Total events	791		1121							
Heterogeneity: Chi ² = 4.43, df = 4 (P = 0.35); i ² = 10%										
Test for overall effect: Z	2 = 0.92 (P = 0.3	6)							
Total (95% CI)		2835		4260	100.0%	1.14 [1.03, 1.27]		•		
Total events	1550		2139							
Heterogeneity: Chi ² = 7	.02, df =	10 (P =	0.72); ²	= 0%						
Test for overall effect: Z	2 = 2.53 (0.2 0.0 T Z 5								
Test for subgroup differ	ences: C	decreased 12DWINSK Increased 12DWINSK								

Figure 3. Forest plot of the association between FABP2 Ala54Thr polymorphism and T2DM: the dominant model (TT + AT versus AA).

0.783). To sum up, the publication bias in this meta-analysis is low. Further sensitivity analysis indicated that potential selection bias did not influence the patterns observed in our study.

Discussion

The FABP2 Ala54Thr gene polymorphism has been suggested as a possible genetic factor associated with dyslipidemia and a higher degree of insulin resistance [26, 27]. However, the results of the studies about the association of the FABP2 Ala54Thr polymorphism with T2DM are conflicting and inconclusive. Thus, we conduct this meta-analysis. Our results found evidence supporting Ala54Thr variant was associated with increased risk of T2DM. These findings may help to explain individual differences of host susceptibility to T2DM. In all kinds of the genetic models except codominant model, the Asian subgroup showed a significant result. On the other side, no significant association was found in other region subgroup in all kinds of models. It is indicated that the variant T allele carrier may increased the risk of T2DM and the risk is related to race.

The following possibilities may make an explanation to this population-specific result. First, T2DM is an extremely complex disease which is related to genetic factors. Thus, different genetic background may leads to this result. According to data from 1000 Genomes Project Phase 1, the T allele frequency of FABP2 Ala54Thr is 27.4% in Asian which is higher than 26.9% in Europen and 24.6% in American [28]. Second, the number of Asian case-control studies is dramatically more than other regions.

Compared with the wild type of FABP2 Ala54Thr, triglycerides excretion was enhanced in Caco-2 cells transfected with a gene with Thr54 mutants [29]. What is more, the Thr54-containing protein have a twofold greater affinity for long-chain fatty acids than those with the Ala54-containing protein [29, 30]. After analysis of lots of case-control studies about the FABP2 Ala54Thr polymorphism and dyslipidemia, it is indicated that the Thr54 allele of the FABP2 Ala54Thr polymorphism may lead to a higher levels of TC and LDL-C, and lower levels of HDL-C, which means the T allele carrier increased the risk of dyslipidemia [26]. Dyslipidemia play an important role in the



Figure 4. Funnel plot of the association between FABP2 Ala54Thr polymorphism and T2DM: the codominant model (AA versus TT).

pathogenesis of insulin resistance and T2DM by impairing peripheral glucose utilization and by promoting hepatic glucose overproduction [31].

Some limitations of the present meta-analysis should be admitted. First, T2DM is a complex disease affected by various factors including multiple genetic factors, environmental stresses and their interactions. Hence, only one single gene polymorphism can't provide the integrated interpretation of genetic risk of T2DM. Second, some unpublished studies were not included in this analysis. Third, the OR estimates of included studies were not adjusted by the same confounders. Some even were presented unadjusted OR. So our results were based on unadjusted OR estimates. Fourth, in the stratified analysis, the Europen and American were pooled in one group, which may cause some inevitable heterogeneity.

In conclusion, this meta-analysis suggested that the FABP2 Ala54Thr gene polymorphism is associated with the risk of T2DM in Asian. However, larger sample size of different ethnic populations, detailed individual information and well designed project will be need for further study.

Acknowledgements

This work was supported by the Zhejiang Provincial Natural Science Foundation (LY13H290003), Zhejiang Provincial Traditional Chinese Medicine Research Foundation and Climbing Plan (2011ZA111), and Taizhou Municipal Science and Technology Foundation (111KYO6O3). We declare that research support played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Disclosure of conflict of interest

None.

Address correspondence to: Dr. Xiaoping Jin, Taizhou Hospital, Affiliated Hospital of Wenzhou

Medical University, Taizhou, Zhejiang, P. R. China. E-mail: lp999111@sohu.com

References

- O'Rahilly S. Genetic factors in type 2 diabetes: the end of the beginning? Science 2005; 307: 370-373.
- [2] Tong Y, Lin Y, Zhang Y, Yang J, Zhang Y, Liu H, Zhang B. Association between TCF7L2 gene polymorphisms and susceptibility to type 2 diabetes mellitus: a large human genome epidemiology (HuGE) review and meta-analysis. BMC Med Genet 2009; 10: 15.
- [3] Yajnik CS, Janipalli CS, Bhaskar S, Kulkarni SR, Freathy RM, Prakash S, Mani KR, Weedon MN, Kale SD, Deshpande J, Krishnaveni GV, Veena SR, Fall CH, McCarthy MI, Frayling TM, Hattersley AT, Chandak GR. FTO gene variants are strongly associated with type 2 diabetes in South Asian Indians. Diabetologia 2009; 52: 247-252.
- [4] Barroso I, Gurnell M, Crowley VE, Agostini M, Schwabe JW, Soos MA, Maslen GL, Williams TD, Lewis H, Schafer AJ, Chatterjee VK, O'Rahilly S. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension. Nature 1999; 402: 880-883.
- [5] Li J, Wu S, Wang M, Wang T, Zhu J. Association of the interleukin-10 -592A/C, -1082G/A and -819T/C gene polymorphisms with type 2 diabetes: a meta-analysis. Gene 2013; 521: 211-216.
- [6] Li Y. ENPP1 K121Q polymorphism and type 2 diabetes mellitus in the Chinese population: a meta-analysis including 11 855 subjects. Metabolism 2012; 61: 625-633.

- [7] Sweetser DA, Birkenmeier EH, Klisak IJ, Zollman S, Sparkes RS, Mohandas T, Lusis AJ, Gordon JI. The human and rodent intestinal fatty acid binding protein genes. A comparative analysis of their structure, expression, and linkage relationships. J Biol Chem 1987; 262: 16060.
- [8] Baier LJ, Sacchettini JC, Knowler WC, Eads J, Paolisso G, Tataranni PA, Mochizuki H, Bennett PH, Bogardus C, Prochazka M. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation, and insulin resistance. J Clin Invest 1995; 95: 1281-1287.
- [9] Alharbi KK, Khan IA, Bazzi MD, Al-Daghri NM, Hasan TN, Alnbaheen MS, Alharbi FK, Al-Sheikh YA, Syed R, Aboul-Soud MA. A54T polymorphism in the fatty acid binding protein 2 studies in a Saudi population with type 2 diabetes mellitus. Lipids Health Dis 2014; 13: 61.
- [10] Raza ST, Fatima J, Ahmed F, Abbas S, Zaidi ZH, Singh S, Mahdi F. Association of angiotensinconverting enzyme (ACE) and fatty acid binding protein 2 (FABP2) genes polymorphism with type 2 diabetes mellitus in Northern India. J Renin Angiotensin Aldosterone Syst 2014; 15: 572-9.
- [11] Tavridou A, Arvanitidis KI, Tiptiri-Kourpeti A, Petridis I, Ragia G, Kyroglou S, Christakidis D, Manolopoulos VG. Thr54 allele of fatty-acid binding protein 2 gene is associated with obesity but not type 2 diabetes mellitus in a Caucasian population. Diabetes Res Clin Pract 2009; 84: 132-137.
- [12] Vimaleswaran KS, Radha V, Mohan V. Thr54 allele carriers of the Ala54Thr variant of FABP2 gene have associations with metabolic syndrome and hypertriglyceridemia in urban South Indians. Metabolism 2006; 55: 1222-1226.
- [13] Albala C, Villarroel A, Santos JL, Angel B, Lera L, Liberman C, Sanchez H, Pérez-Bravo F. FABP2 Ala54Thr polymorphism and diabetes in Chilean elders. Diabetes Res Clin Pract 2007; 77: 245-250.
- [14] Fisher E, Li Y, Burwinkel B, Kühr V, Hoffmann K, Möhlig M, Spranger J, Pfeiffer A, Boeing H, Schrezenmeir J, Döring F. Preliminary evidence of FABP2 A54T polymorphism associated with reduced risk of type 2 diabetes and obesity in women from a German cohort. Horm Metab Res 2006; 38: 341-345.
- [15] Boullu-Sanchis S, Leprêtre F, Hedelin G, Donnet JP, Schaffer P, Froguel P, Pinget M. Type 2 diabetes mellitus: association study of five candidate genes in an Indian population of Guadeloupe, genetic contribution of FABP2 polymorphism. Diabetes Metab 1999; 25: 150-156.

- [16] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-188.
- [17] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22: 719-748.
- [18] Egger M, Davey SG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634.
- [19] Bu L, Salto LM, De Leon KJ, De Leon M. Polymorphisms in fatty acid binding protein 5 show association with type 2 diabetes. Diabetes Res Clin Pract 2011; 92: 82-91.
- [20] Tahvanainen E, Molin M, Vainio S, Tiret L, Nicaud V, Farinaro Masana L, Ehnholm C. Intestinal fatty acid binding protein polymorphism at codon 54 is not associated with postprandial responses to fat and glucose tolerance tests in healthy young Europeans. Results from EARS II participants. Atherosclerosis 2000; 152: 317-325.
- [21] Hayakawa T, Nagai Y, Nohara E, Yamashita H, Takamura T, Abe T, Nomura G, Kobayashi K. Variation of the fatty acid binding protein 2 gene is not associated with obesity and insulin resistance in Japanese subjects. Metabolism 1999; 48: 655-657.
- [22] Lei HH, Coresh J, Shuldiner AR, Boerwinkle E, Brancati FL. Variants of the insulin receptor substrate-1 and fatty acid binding protein 2 genes and the risk of type 2 diabetes, obesity, and hyperinsulinemia in African-Americans: the Atherosclerosis Risk in Communities Study. Diabetes 1999; 48: 1868-1872.
- [23] Ito K, Nakatani K, Fujii M, Katsuki A, Tsuchihashi K, Murata K, Goto H, Yano Y, Gabazza EC, Sumida Y, Adachi Y. Codon 54 polymorphism of the fatty acid binding protein gene and insulin resistance in the Japanese population. Diabet Med 1999; 16: 119.
- [24] Xiang K, Zheng T, Jia W, Sun D, Ding W, Lu J, Tang J. The impact of codon 54 variation in intestinal fatty acid binding protein gene on the pathogenesis of diabetes mellitus in Chinese. Chin Med J (Engl) 1999; 112: 99-102.
- [25] Yamada K, Yuan X, Ishiyama S, Koyama K, Ichikawa F, Koyanagi A, Koyama W, Nonaka K. Association between Ala54Thr substitution of the fatty acid-binding protein 2 gene with insulin resistance and intra-abdominal fat thickness in Japanese men. Diabetologia 1997; 40: 706-710.
- [26] Zhao T, Nzekebaloudou M, Lv J. Ala54Thr polymorphism of fatty acid-binding protein 2 gene and fasting blood lipids: a meta-analysis. Atherosclerosis 2010; 210: 461-467.
- [27] Zhao T, Zhao J, Yang W. Association of the fatty acid-binding protein 2 gene Ala54Thr polymorphism with insulin resistance and blood glucose: a meta-analysis in 13451 subjects. Diabetes Metab Res Rev 2010; 26: 357-364.

- [28] Pybus M, Dall'Olio GM, Luisi P, Uzkudun M, Carreño-Torres A, Pavlidis P, Laayouni H, Bertranpetit J, Engelken J. 1000 Genomes Selection Browser 1.0: a genome browser dedicated to signatures of natural selection in modern humans. Nucleic Acids Res 2013; 42: D903-D909.
- [29] Bogardus C. A Polymorphism in the Human Intestinal Fatty Acid Binding Protein Alters Fatty Acid Transport across Caco-2 Cells. J Biol Chem 1996; 271: 10892-10896.
- [30] Levy E, Ménard D, Delvin E, Stan S, Mitchell G, Lambert M, Ziv E, Feoli-Fonseca JC, Seidman E. The Polymorphism at Codon 54 of the FABP2 Gene Increases Fat Absorption in Human Intestinal Explants. J Biol Chem 2001; 276: 39679-39684.
- [31] Boden G. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 1997; 46: 3-10.